Prescient Therapeutics: Investor Briefing with CEO James McDonnell
CEO James McDonnell, held a shareholder briefing with Reach Markets.
In this session, James discussed:
- How EMA Orphan Drug Designation for PTX-100 complements existing U.S. FDA Orphan Drug and Fast Track status.
- Progress of the Phase 2a study for cancer treatment PTX-100 as they move closer toward commercialisation in key markets.
- The sub-analysis of CTCL in Phase 1b where patients exhibited a 100% clinical benefit rate with no serious adverse events.
- Their First-in-class technology which could apply to 22% of all cancer cases.
Recorded on 25th November 2025 at 3pm (AEDT)
Featured Speaker
James McDonnell
CEO
James McDonnell is a seasoned leader in the biopharmaceutical industry, bringing over 25 years of global experience in pharmaceuticals, with a particular focus on blood disorders and hematological malignancies such as Myeloma, Myelodysplasia, and CML.
Throughout his career, James has held senior leadership roles at renowned pharmaceutical companies, including Pharmion and CSL Vifor. At Pharmion, he spearheaded the growth of its oncology and hematology portfolio as Head of Global Marketing, contributing to the company’s acquistion by Celgene Corporation for US$2.9 billion. Most recently, James served as Global Commercial Lead for Patient Blood Management at CSL Vifor, where he drove key enterprise-wide strategic initiatives.
James is a registered pharmacist and a member of the Royal Pharmaceutical Society. He holds a Graduate Diploma in Marketing from Monash University and is a graduate of the Australian Institute of Company Directors.
